Quick Answer
Protalix BioTherapeutics, Inc. reported Research And Development Expense of $19.57 million for the year ending 2025.
- Protalix BioTherapeutics, Inc. showed an increase of +50.9% in Research And Development Expense from 2024 to 2025.
- This data is from Protalix BioTherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), Protalix BioTherapeutics, Inc.'s Research And Development Expense has declined by 28.6%.
- Historical annual values: Fiscal year 2025: $19.57 million | Fiscal year 2024: $12.97 million | Fiscal year 2023: $17.09 million | Fiscal year 2022: $29.35 million | Fiscal year 2021: $29.73 million | Fiscal year 2020: $38.17 million | Fiscal year 2019: $44.62 million | Fiscal year 2018: $33.33 million | Fiscal year 2017: $32.17 million | Fiscal year 2016: $30.41 million | Fiscal year 2015: $24.89 million | Fiscal year 2014: $27.35 million | Fiscal year 2013: $29.23 million | Fiscal year 2012: $36.67 million | Fiscal year 2011: $37.82 million | Fiscal year 2010: $37.69 million | Fiscal year 2009: $27.39 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: